Bio-Reference Laboratories
481 Edward H Ross Dr, Elmwood Park, NJ, 07407, United States
Overview
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Health Diagnostics
- Hospitality
Investment portfolio
- IncellDx
Led · Convertible Note · Apr 2012
InCellDx develops cell-based instruments and in-situ hybridization methods to quantify protein and gene expression within intact cells, enabling measurement by distinct cell type for improved diagnosis and disease localization. The company targets detection and monitoring of life‑threatening conditions including cervical cancer, breast cancer, HIV/AIDS, hepatitis and transplant rejection. Its patented technology has been adapted by GenPath for quantification of E6/E7 mRNA in HPV. In conjunction with the investment, BRLI’s GenPath Women’s Health developed and launched a test called GenCerv based on InCellDx’s HPV mRNA quantification technology. The company is led by founder and CEO Bruce Patterson, MD, and is based in Menlo Park, California. IncellDx develops molecular diagnostic products, including an E6/E7 mRNA test called HPV OncoTect intended to detect and quantify oncogenes that drive progression to cervical cancer. The company plans to use recently raised funds to advance commercialization of its product portfolio and to start a U.S. clinical trial for HPV OncoTect. IncellDx positions HPV OncoTect as addressing the lack of specificity in existing U.S. high-risk HPV screening products. The article cites the U.S. high-risk HPV testing market as roughly $300M and growing at about 14% annually. The company is based in Menlo Park, California. The investors in the reported round were not disclosed.
Team
No current team members are available.